Author, as appears in the article.: Holmes, M.V. Simon, T. Exeter, H.J Folkersen, L. Asselbergs, F.W. Guardiola, M. Cooper, J.A. Palmen, J. Hubacek, J.A. Carruthers, K.F. Horne, B.D. Brunisholz, K.D. Mega, J.L. Van Iperen, E.P. Li, M. Leusink, M. Trompet, S. Verschuren, J.J. Hovingh, G.K. Dehghan, A. Nelson, C.P. Kotti, S. Danchin, N. Scholz, M. Haase, C.L. Rothenbacher, D. Swerdlow, D.I. Kuchenbaecker, K.B. Staines-Urias, E. Goel, A. Van 't Hooft, F. Gertow, K. De Faire, U. Panayiotou, A.G. Tremoli, E., Baldassarre, D. Veglia, F. Holdt, L.M. Beutner, F. Gansevoort. R.T. Navis, G.J. Mateo, L.I. Breitling, L.P. Brenner, H. Thiery, J. Dallmeier, D. Franco-Cereceda, A. Boer, J.M. Stephens, J.W. Hofker, M.H. Tedgui, A. Hofman, A. Uitterlinden, A.G. Adamkova, V. Pitha, J. Onland-Moret, N.C. Cramer, M.J. Nathoe, H.M. Spiering, W. Klungel, O.H. Kumari, M. Whincup, P.H. Morrow, D.A. Braund, P.S. Hall, A.S. Olsson, A.G. Doevendans, P.A. Trip, M.D. Tobin, M.D. Hamsten, A. Watkins, H. Koenig, W. Nicolaides, A.N. Teupser, D. Day, I.N. Carlquist, J.F. Gaunt, T.R. Ford, I. Sattar, N. Tsimikas, S. Schwartz, G.G. Lawlor, D.A. Morris, R.W. Sandhu, M.S. Poledne, R. Maitland-van der Zee, A.H. Khaw, K.T. Keating, B.J. Van der Harst, P. Price, J.F. Mehta, S.R. Yusuf, S. Witteman, J.C. Franco, O.H. Jukema, J.W. De Knijff, P. Tybjaerg-Hansen, A. Rader, D.J. Farrall, M. Samani, N.J. Kivimaki, M. Fox, K.A. Humphries, S.E. Anderson, J.L. Boekholdt, S.M. Palmer, T.M. Eriksson, P. Paré, G. Hingorani, A.D. Sabatine, M.S. Mallat, Z. Casas, J.P. Talmud, P.J.
Department: Medicina i Cirurgia
e-ISSN: 1558-3597
URV's Author/s: Guardiola, M. Michael V Holmes, Lasse Folkersen, Tabassome Simon
Keywords: Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization
Abstract: This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 0735-1097
Last page: 1976
Journal volume: 62
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.sciencedirect.com/science/article/pii/S0735109713027782?via%3Dihub
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: https://doi.org/10.1016/j.jacc.2013.06.044
Entity: Universitat Rovira i Virgili.
Journal publication year: 2013
First page: 1966
Repositori URV